Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Current evidence suggests that patients with Luminal A early breast cancer can skip chemotherapy or extended endocrine therapy, but immunohistochemistry-based biomarker analysis for St Gallen subtyping may not...

Source: BMC Cancer - July 15, 2019 Category: Cancer & Oncology Authors: Mark Laible, Kerstin Hartmann, Claudia G ürtler, Tobias Anzeneder, Ralph Wirtz, Stephan Weber, Thomas Keller, Ugur Sahin, Martin Rees and Annette Ramaswamy Tags: Research article Source Type: research